Skip to content

PanTher Therapeutics

7 viewers · 30d

Total raised

$3.0M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $3.0M
ROUNDS
1
INVESTORS
26
FOUNDED
N/A
HQ
Austin, TX
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
7

AI overview

Updated

PanTher Therapeutics, Inc. is a clinical-stage oncology company that focuses on revolutionizing cancer treatment through localized therapy. By addressing the inefficiencies of systemic drug delivery, PanTher aims to enhance cancer therapies and minimize side effects for patients.

What sets it apart

PanTher stands out by delivering high-dose therapeutic agents directly to tumor sites, significantly minimizing systemic toxicity while maximizing drug effectiveness.

Funding history

1 round
Equity+2Mar 14, 2025
Form D
+$3.0M$3.0M total

Latest SEC filings

via EDGAR · CIK 0001644045
Form D · Mar 14, 2025View on EDGAR

Products

1 tracked

PTM-101

Oncology therapy

PTM-101 is an innovative, absorbable polymer film designed to deliver paclitaxel, a potent chemotherapy agent, directly to the peritumoral region. This targeted delivery method allows for sustained, high-dose administration while avoiding the systemic side effects typically associated with chemotherapy.

  • Flexible polymer film design
  • Continuous high-dose delivery directly to tissues
  • Reduces systemic side effects of traditional chemotherapy
  • Utilizes proprietary Sagittari™ platform for customization

Links

WebsiteSEC EDGAR filings